Quick Facts: Main Uses

• Relieves symptoms of Osteoarthritis
• Aids in the management of Rheumatoid Arthritis
• Helps manage discomfort associated with Ankylosing Spondylitis
• Provides temporary relief for acute pain, such as post-dental surgery discomfort

---

What Nucoxia-P Treats: Main Uses and Benefits

Nucoxia-P is a combination product used to help manage pain and inflammation in adults. It is typically prescribed for short-term relief of discomfort associated with various musculoskeletal and joint conditions.

The medication is indicated for the symptomatic relief of conditions that affect the joints and spine. This includes providing relief from the pain and swelling associated with Osteoarthritis and aids in the management of Rheumatoid Arthritis and Ankylosing Spondylitis. It also provides temporary relief for specific episodes of acute pain, such as pain following dental procedures or other acute conditions.

The combined components work to help reduce both pain perception and inflammation, contributing to an improvement in overall function and comfort. This medicine is utilized for the management of arthritis and other painful inflammatory conditions.

This medication is a component of a comprehensive treatment plan that may include other therapies to manage the underlying conditions.

Who Can and Cannot Use Nucoxia-P?

Regulatory agencies define strict eligibility criteria for the use of Nucoxia-P (Etoricoxib/Acetaminophen), primarily based on age, pre-existing conditions, and organ function, due to the component Etoricoxib.

---

Contraindications and Non-Eligibility

Nucoxia-P is contraindicated and must not be used by several specific populations:

• Age: Children and adolescents under 16 years of age.
• Hypersensitivity: Patients allergic to etoricoxib, acetaminophen/paracetamol, or those who have had allergic reactions (e.g., bronchospasm) to aspirin or other NSAIDs.
• Gastrointestinal Health: Individuals with active peptic ulceration, active GI bleeding, or Inflammatory Bowel Disease.
• Organ Function: Patients with severe hepatic dysfunction (Child-Pugh score ge 10) or severe renal impairment (creatinine clearance <30 ml/min).
• Cardiovascular Disease: Patients with Congestive Heart Failure (NYHA II–IV), uncontrolled hypertension (persistently above 140/90 mmHg), or established ischaemic heart disease/cerebrovascular disease.
• Reproductive Status: Women who are pregnant or breastfeeding.

---

Conditional Use and Restrictions

Use is established only for adults and adolescents 16 years of age and older who do not have the above contraindications.

• Caution is advised for elderly patients (65 years and older).
• Conditional use applies to those with mild to moderate hepatic impairment or a history of gastrointestinal disease, requiring careful medical supervision.
• Patients with cardiovascular risk factors (e.g., controlled hypertension, diabetes) should only use the medicine after careful consideration of their individual risk profile.

Nucoxia-P contains Etoricoxib and Paracetamol, and its interaction profile is based on the known risks associated with both active components. Co-administration with other Paracetamol-containing products is strictly advised against to prevent exceeding maximum dosage thresholds and risking liver damage. Use of Alcohol is also considered unsafe as it may increase the risk of liver toxicity and gastrointestinal bleeding.

Documented Drug Interactions

The product may interact with several drug classes, potentially requiring dose adjustments or increased monitoring. Anticoagulants (e.g., Warfarin) carry an increased risk of bleeding. Caution is required with Lithium and Methotrexate, as this medication may increase the blood levels of both drugs, potentially leading to toxicity. Diuretics and Antihypertensive medicines (e.g., ACE inhibitors, Angiotensin II receptor antagonists) may have their efficacy reduced, and the combination may increase the risk of kidney problems.

Concomitant use with Cyclosporin or Tacrolimus can increase the risk of nephrotoxicity. Cholestyramine should be taken with a minimum two-hour interval, and oral contraceptives require a minimum twelve-hour interval to manage absorption and hormone levels, respectively. Co-administration with other Non-Steroidal Anti-inflammatory Drugs (NSAIDs), including low-dose Aspirin, should be done with caution due to the increased risk of adverse effects, particularly gastrointestinal complications.

How Nucoxia-P Works

The physiological action of Nucoxia-P arises from its two active components, each targeting complementary biochemical pathways to modulate systemic responses.

---

Selective Targeting of Peripheral Mediators

This domain focuses on Etoricoxib's action as a highly specific inhibitor of the Cyclooxygenase-2 (COX-2) enzyme. By blocking the COX-2 pathway at the molecular level, the drug suppresses the peripheral generation of prostaglandins—key signaling molecules involved in local tissue responses. This mechanism results in a limitation of mediator production, contributing to the modulation of peripheral tissue reactivity.

---

Modulation of Central Nervous System Signaling

This domain involves the primary mechanism of Paracetamol, which is concentrated within the Central Nervous System (CNS). It acts by modulating prostaglandin synthesis and possibly influencing descending inhibitory pathways in the brain and spinal cord. This action alters the central transmission and perception of nociceptive signals, leading to predictable physiological adjustments in the central processing of afferent signals and its thermoregulatory response.

---

Dual-Level Mechanistic Synergy

The overall effect profile is shaped by the concurrent dual-level mechanism, where COX-2 inhibition limits signal generation at the source (periphery) while central modulation adjusts signal processing (CNS). This synergistic activity influences both peripheral and central pathways, contributing to a dual modulation of the physiological cascade.

How Nucoxia-P is Used: Official Administration Guidelines

Nucoxia-P is a fixed-dose combination medicine administered exclusively via the oral route in tablet form. Its usage pattern emphasizes a constrained dose and limited duration of use.

---

The standard regimen for the symptomatic management of chronic conditions is once daily, with the dose strictly limited by the 60 mg Etoricoxib component. This regimen must be adhered to using the lowest effective dose for the shortest duration possible, a fundamental principle governing the use of the medicine. For patients requiring relief from acute pain, treatment is typically restricted to a short period, often no longer than eight days.

---

Intake Conditions and Constraints

The tablet must be physically administered by being swallowed whole with water; the tablet must not be crushed, broken, or chewed. The medicine may be taken with or without food, although taking it without food may lead to a faster onset of its therapeutic effect. The schedule is not tied to a specific time of day but rather to the once-daily frequency.

---

Population-Specific Rules

Specific administrative rules apply to certain patient groups. The use of this medicine is contraindicated in children and adolescents under 16 years of age. Furthermore, the drug is not recommended for patients who have severe hepatic impairment (liver dysfunction) or those with severe renal impairment where creatinine clearance is below 30 ml/min.

Research evidence / Overview of studies for Nucoxia-P

---

Evidence for Symptomatic Relief in Osteoarthritis

The research on the main component was evaluated in Osteoarthritis (OA) and primarily consists of short-term and intermediate-term Randomized Controlled Trials (RCTs). These studies examined changes in patient-reported outcomes describing perceived discomfort, specifically pain, and outcomes reflecting daily functioning or activity level in adults with OA of the hip and knee. Systematic Reviews and Meta-analyses were used in research exploring how symptoms change over time in these conditions characterized by fluctuating or episodic manifestations.

Findings describe patterns observed in the studies regarding how patients reported their experience during the study period. Data show patterns related to patient-reported scores for pain and physical function. The evidence contributes to understanding symptom patterns in these chronic conditions.

What remains uncertain is the full profile of long-term symptomatic changes. There is limited information for long-term outcomes that track the durability of observed changes for more than one year. Additionally, comparative evidence is lacking for the specific fixed-dose combination (Nucoxia-P) when directly compared to other established treatment combinations was studied for OA.

---

Evidence for Managing Rheumatoid Arthritis and Ankylosing Spondylitis

For Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS), the primary component was evaluated in double-blind, controlled RCTs. These trials enrolled adults with conditions involving periods of heightened symptoms. The research examined standardized measures, such as outcomes capturing phases of heightened symptom activity (disease activity scores) and detailed counts of tender or swollen joints. These measurements were used in research exploring how symptoms change over time in these conditions marked by functional limitations.

Studies monitored how symptoms evolved in the observed populations with RA and AS, with core comparative trials typically lasting around 12 weeks. The findings describe patterns observed in the studies related to these standardized disease activity measurements during the study period.

However, research describing long-term outcomes for specific subgroup findings are uncertain, particularly for patients with AS beyond a year. Furthermore, the existing evidence for the specific Etoricoxib/Acetaminophen combination (Nucoxia-P) is limited when comparing it directly against the data for the primary ingredient used alone.

---

Research Gaps and Areas of Uncertainty

Multiple research limitation frames remain relevant for this medicine. Data for the specific fixed-dose combination product (Nucoxia-P) are still emerging, and direct comparative evidence is lacking against other dual-agent combination treatments for the indications studied.

Additionally, while the primary component was studied for chronic conditions, there is limited information for long-term outcomes regarding symptomatic change and function. The results apply only to the populations studied in the RCTs, and data for certain patient groups, such as those with certain pre-existing comorbidities, remain insufficient. The studies help show what has been observed so far, but the evidence highlights what is known — and what is still uncertain.

Common questions about Nucoxia-P (FAQ)

---

Q: How quickly should I expect Nucoxia-P to start working?

Official product information suggests that the maximum concentration of the Etoricoxib component in the bloodstream is typically reached about one hour after the tablet is taken in a fasted state. Regulatory documents describe that taking the medicine without food may lead to a faster onset of its therapeutic effect.

---

Q: How long does the effect of one dose of Nucoxia-P typically last?

The medicine is designed for a once-daily dosing schedule. This frequency is supported by pharmacokinetic data which shows that the Etoricoxib component has an elimination half-life of approximately 20 to 22 hours.

---

Q: What is the primary function of the 'P' ingredient in Nucoxia-P?

The 'P' ingredient, which is Paracetamol, is included primarily as an analgesic (pain reliever) and antipyretic (fever reducer). It acts by modulating chemical signaling in the Central Nervous System (CNS) to influence the body's pain threshold and help regulate body temperature.

---

Q: What organs of the body can be affected by Nucoxia-P over time?

Official safety documents identify potential effects on several major systems. Risks are identified for the cardiovascular system (including thrombotic events like heart attack and stroke), the liver (risk of hepatotoxicity), and the kidneys (changes in renal function). These risks are typically described as dose- and duration-dependent.

---

Q: Can Nucoxia-P interact with common vitamins or supplements?

Official product labeling requires the disclosure of all medicines, vitamins, herbal remedies, and dietary supplements to a healthcare professional. This is necessary because these products may potentially interfere with the medicine's effects or safety profile.

---

Q: Are the two components in Nucoxia-P released into the body at the same time?

The product is a fixed-dose combination tablet. Pharmacokinetic data for the individual ingredients indicate that both are rapidly absorbed, with their maximum blood concentrations occurring shortly after oral administration.

---

Q: Does Nucoxia-P affect sleep patterns?

Official documentation lists sleep disturbances as an uncommon adverse effect. Other documented effects that may influence rest and alertness include dizziness and a feeling of drowsiness.

---

Q: Does the efficacy of Nucoxia-P decrease over time with continued use?

Studies examining the use of the primary component indicate that there is limited information available on long-term outcomes. Research has not fully tracked the durability of symptomatic changes for periods longer than one year.

---

Q: Are there any common foods or drinks that interact with Nucoxia-P?

Regulatory information notes that the medicine can be taken with or without food. Although taking it without food may lead to a faster effect, common food consumption is not generally described as significantly affecting the overall absorption of the Etoricoxib component.

---

Q: Is it common to feel drowsy or sleepy after taking Nucoxia-P?

Official documentation lists dizziness as a commonly reported adverse effect. Less common effects that may impact alertness include drowsiness and sleep disturbances.

---

Q: Is Nucoxia-P safe for long-term use?

Official regulatory documents define the conditions of use, stating that the medicine is to be used for the shortest duration possible and at the lowest effective daily dose. This is due to official warnings describing the risk of certain serious side effects, particularly cardiovascular events, as being dependent on both the dose and the duration of use.

---

Q: Is Nucoxia-P available over the counter?

Based on regulatory classifications in many countries, the medicine is categorized as a Prescription Only Medicine (POM) due to the inclusion of Etoricoxib. It is not typically sold over the counter.

---

Q: Is it possible to become dependent on Nucoxia-P?

The active components, Etoricoxib and Paracetamol, are non-opioid medications. Regulatory documents do not classify this drug as an opioid or controlled substance, and they do not list dependence or addiction as associated risks.

---

Q: Is Nucoxia-P a controlled substance?

The medicine is generally categorized as a Prescription Only Medicine (POM). Based on the legal classifications in major jurisdictions, it is not typically listed as a Schedule I-V controlled substance.

The storage and disposal of Nucoxia-P tablets are governed by regulatory requirements to maintain drug quality and ensure safety.

Storage Scope	Official Requirement
Temperature	Store below 30 C
Protection	Must be protected from light and moisture
Container	Store in the original container and keep it tightly closed
Child Safety	Keep out of the sight and reach of children

These official instructions define that the product must be kept under controlled temperature and environmental conditions to prevent degradation. Unused or expired Nucoxia-P must not be disposed of via wastewater or household waste; disposal must follow local regulations for pharmaceutical waste to prevent environmental risk.